The Peruvian market is dominated by a few major players, but SMEs like D & M Pharma Peru SAC serve niche markets. The 2024-2025 market is characterized by:
Based on regulatory filings and import records, their portfolio includes: D & M Pharma Peru S.A.C. Company Profile - EMIS
The company adheres to Good Storage Practices (BPA) and local Peruvian technical standards to ensure pharmaceutical quality. D&M Pharma Perú S.A.C. d amp m pharma peru sac
The company's structure is composed of , which demonstrate its commitment to providing specialized healthcare solutions:
For medical inquiries, pharmacovigilance reports, or commercial inquiries, you can reach the company through their official website : The Peruvian market is dominated by a few
: Specialized solutions for nebulization and aerosol therapy designed for chronic respiratory conditions.
The company maintains robust drug safety protocols to monitor and report adverse events to the (the Peruvian regulatory authority). Recent Leadership & Recognition D&M Pharma Perú S
: Aerotrop HFA, Butocort HFA, Fluticort HFA, and Neumocort HFA.
The acronym stands for Sociedad Anónima Cerrada (Closed Joint-Stock Company). This is a common corporate structure in Peru used by medium to large enterprises. For D & M Pharma, operating as an SAC implies:
Available in aerosol inhaler formats (125 mcg and 250 mcg), treating asthma and allergic rhinitis.
Products such as Neumocort HFA and Aerotrop for inhalation and nebulization.